REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 21st, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2023, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors signatory hereto. Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement, by and among the Company and the Investors, dated as of August 15, 2023 (the “Purchase Agreement”) unless otherwise defined herein.
ii- 3.6 Capitalization ........................................................ ........................................................... 29 3.7 SEC Filings; Financial Statements; Internal Controls...Agreement and Plan of Merger and Reorganization • August 21st, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 21st, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2023, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
SKYE BIOSCIENCE, INC. SECURED NOTE AND WARRANT PURCHASE AGREEMENTSecured Note and Warrant Purchase Agreement • August 21st, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations • California
THIS SECURED NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as of August 15, 2023 by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and MFDI, LLC, a California limited liability company (“Investor”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 21st, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations • Nevada
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made and entered into on ______________, 2023, by and between Skye Bioscience, Inc., a Nevada corporation (the “Company”), and ______________ (“Indemnitee”).
